Two Boston-area biotechs focused on kidney disease, Keryx and Akebia, to merge
Two Boston-area biotech firms that specialize in drugs for chronic kidney disease — Cambridge-based Akebia Therapeutics and Boston-based Keryx Biopharmaceuticals — will merge and form a company worth $1.3 billion.
On Thursday morning, the two companies announced that both boards have approved the plan. The combined company will be named Akebia Therapeutics (Nasdaq: AKBA) and will be led by that company’s CEO, John Butler.
The two companies would have more than 300 combined employees, barring…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Source Type: news
More News: American Health | Biotechnology | Chronic Kidney Disease | Health Management | Urology & Nephrology